Macrophage plasticity and polarization in tissue repair and remodelling

Journal of Pathology

Volumn 229, Issue 2, 2013, Pages 176-185

  Mantovani, Alberto ^a,b   Biswas, Subhra K ^c   Galdiero, Maria Rosaria ^a,d   Sica, Antonio ^a,e   Locati, Massimo ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c AGENCY FOR SCIENCE   (Singapore)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

activation; healing; macrophage; polarization; resolution; tissue remodelling; tissue repair

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

CELL INTERACTION; CELL LINEAGE; HOMEOSTASIS; HUMAN; INFLAMMATION; MACROPHAGE; MONOCYTE; NEOPLASM; NONHUMAN; PHENOTYPE; PLASTICITY; POLARIZATION; PRIORITY JOURNAL; REVIEW; STEM CELL; TISSUE REPAIR; WOUND HEALING;

ANIMALS; CELL DIFFERENTIATION; HOMEOSTASIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGE ACTIVATION; MACROPHAGES; NEOPLASMS; PHENOTYPE; STEM CELLS; WOUND HEALING;

EID: 84871076444     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4133     Document Type: Review

References (144)

1. Gordon S, Martinez FO,. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593-604.
2. Biswas SK, Mantovani A,. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-896.
3. Sica A, Bronte V,. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155-1166. (Pubitemid 46718400)
4. Mantovani A, Sozzani S, Locati M, et al,. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555. (Pubitemid 35223554)
5. Mosser DM, Edwards JP,. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
6. Gordon S,. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35. (Pubitemid 37328697)
7. Sica A, Mantovani A,. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787-795.
8. Geissmann F, Manz MG, Jung S, et al,. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-661.
9. Schulz C, Gomez Perdiguero E, Chorro L, et al,. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012; 336: 86-90.
10. Nakajima H, Uchida K, Guerrero AR, et al,. Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury. J Neurotrauma 2012; 29: 1614-1625.
11. Ohta S, Misawa A, Fukaya R, et al,. Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. J Cell Sci 2012; 125: 3210-3220.
12. Okuda H, Kobayashi A, Xia B, et al,. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res 2012; 72: 537-547.
13. Anton K, Banerjee D, Glod J,. Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PloS One 2012; 7: e35036.
14. Wu A, Wei J, Kong LY, et al,. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-oncology 2010; 12: 1113-1125.
15. Ye XZ, Xu SL, Xin YH, et al,. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol 2012; 189: 444-453.
16. Jinushi M, Baghdadi M, Chiba S, et al,. Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res 2012; 2: 529-539.
17. Jinushi M, Chiba S, Yoshiyama H, et al,. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA 2011; 108: 12425-12430.
18. Kim J, Hematti P,. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009; 37: 1445-1453.
19. Klimchenko O, Di Stefano A, Geoerger B, et al,. Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. Blood 2011; 117: 3065-3075.
20. Lolmede K, Campana L, Vezzoli M, et al,. Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J Leukoc Biol 2009; 85: 779-787.
21. Ding J, Jin W, Chen C, et al,. Tumor associated macrophage x cancer cell hybrids may acquire cancer stem cell properties in breast cancer. PloS One 2012; 7: e41942.
22. Erreni M, Solinas G, Brescia P, et al,. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer 2010; 46: 3383-3392.
23. Guilloton F, Caron G, Menard C, et al,. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 2012; 119: 2556-2567.
24. Gyorki DE, Asselin-Labat ML, van Rooijen N, et al,. Resident macrophages influence stem cell activity in the mammary gland. Breast Cancer Res 2009; 11: R62.
25. Hoeffel G, Wang Y, Greter M, et al,. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J Exp Med 2012; 209: 1167-1181.
26. Freytes DO, Kang JW, Marcos I, et al,. Macrophages modulate the viability and growth of human mesenchymal stem cells. J Cell Biochem 2012; Epub ahead of print doi:10.1002/jcb.24357.
27. Gordon S, Taylor PR,. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964. (Pubitemid 41746764)
28. Hazlett LD, McClellan SA, Barrett RP, et al,. IL-33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2010; 51: 1524-1532.
29. Kurowska-Stolarska M, Stolarski B, Kewin P, et al,. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009; 183: 6469-6477.
30. Pesce J, Kaviratne M, Ramalingam TR, et al,. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 2006; 116: 2044-2055. (Pubitemid 44033328)
31. Hamilton JA,. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-544. (Pubitemid 351913679)
32. Lacey DC, Achuthan A, Fleetwood AJ, et al,. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol 2012; 188: 5752-5765.
33. Bergenfelz C, Medrek C, Ekstrom E, et al,. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J Immunol 2012; 188: 5448-5458.
34. Mantovani A, Sica A, Sozzani S, et al,. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686. (Pubitemid 39457982)
35. Titos E, Rius B, Gonzalez-Periz A, et al,. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 2011; 187: 5408-5418.
36. Uderhardt S, Herrmann M, Oskolkova OV, et al,. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 2012; 36: 834-846.
37. Gustafsson C, Mjosberg J, Matussek A, et al,. Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. PloS One 2008; 3: e2078.
38. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al,. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 2007; 447: 1116-1120. (Pubitemid 47014427)
39. Rae F, Woods K, Sasmono T, et al,. Characterisation and trophic functions of murine embryonic macrophages based upon the use of a Csf1r-EGFP transgene reporter. Dev Biol 2007; 308: 232-246. (Pubitemid 47087792)
40. Raes G, Brys L, Dahal BK, et al,. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol 2005; 77: 321-327. (Pubitemid 40289561)
41. Auffray C, Fogg D, Garfa M, et al,. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007; 317: 666-670. (Pubitemid 47229966)
42. Biswas SK, Mantovani A,. Orchestration of metabolism by macrophages. Cell Metab 2012; 15: 432-437.
43. Dinarello CA,. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-1359. (Pubitemid 40664079)
44. Noel W, Raes G, Hassanzadeh Ghassabeh G, et al. Alternatively activated macrophages during parasite infections. Trends Parasitol 2004; 20: 126-133. (Pubitemid 38264445)
45. Wynn TA,. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-594.
46. Chawla A, Nguyen KD, Goh YP,. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011; 11: 738-749.
47. Nguyen KD, Qiu Y, Cui X, et al,. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 2011; 480: 104-108.
48. Fridlender ZG, Sun J, Kim S, et al,. Polarization of tumor-associated neutrophil phenotype by TGFβ: N1' versus N2' TAN. Cancer Cell 2009; 16: 183-194.
49. Tsuda Y, Takahashi H, Kobayashi M, et al,. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 2004; 21: 215-226. (Pubitemid 39094051)
50. Mantovani A, Cassatella MA, Costantini C, et al,. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11: 519-531.
51. Mantovani A,. From phagocyte diversity and activation to probiotics: back to Metchnikoff. Eur J Immunol 2008; 38: 3269-3273.
52. Martinez FO, Gordon S, Locati M, et al,. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177: 7303-7311. (Pubitemid 44715100)
53. Gleissner CA, Shaked I, Little KM, et al,. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010; 184: 4810-4818.
54. + peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009; 284: 34342-34354.
55. Nizet V, Johnson RS,. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009; 9: 609-617.
56. Rodriguez-Prados JC, Traves PG, Cuenca J, et al,. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol 2010; 185: 605-614.
57. Vats D, Mukundan L, Odegaard JI, et al,. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab 2006; 4: 13-24. (Pubitemid 43942258)
58. MacMicking J, Xie QW, Nathan C,. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-350. (Pubitemid 27169284)
59. Pesce JT, Ramalingam TR, Mentink-Kane MM, et al,. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathogens 2009; 5: e1000371.
60. Van den Bossche J, Lamers WH, Koehler ES, et al,. Pivotal advance: arginase-1-independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes. J Leukoc Biol 2012; 91: 685-699.
61. Corna G, Campana L, Pignatti E, et al,. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 2010; 95: 1814-1822.
62. Recalcati S, Locati M, Marini A, et al,. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol 2010; 40: 824-835.
63. Cairo G, Recalcati S, Mantovani A, et al,. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol 2011; 32: 241-247.
64. Schioppa T, Uranchimeg B, Saccani A, et al,. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198: 1391-1402. (Pubitemid 37392484)
65. Riboldi E, Porta C, Morlacchi S, et al,. Hipoxia regulation of macrophage functions in pathophysiology Int Immunol 2012; (in press).
66. Lawrence T, Natoli G,. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011; 11: 750-761.
67. Pollard JW,. Trophic macrophages in development and disease. Nat Rev Immunol 2009; 9: 259-270.
68. London A, Itskovich E, Benhar I, et al,. Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. J Exp Med 2011; 208: 23-39.
69. Uccelli A, Moretta L, Pistoia V,. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736.
70. Palani S, Maksimow M, Miiluniemi M, et al,. Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages. Eur J Immunol 2011; 41: 2052-2063.
71. Nagamatsu T, Schust DJ,. The contribution of macrophages to normal and pathological pregnancies. Am J Reprod Immunol 2010; 63: 460-471.
72. Houser BL, Tilburgs T, Hill J, et al,. Two unique human decidual macrophage populations. J Immunol 2011; 186: 2633-2642.
73. Svensson J, Jenmalm MC, Matussek A, et al,. Macrophages at the fetal-maternal interface express markers of alternative activation and are induced by M-CSF and IL-10. J Immunol 2011; 187: 3671-3682.
74. Laskarin G, Cupurdija K, Tokmadzic VS, et al,. The presence of functional mannose receptor on macrophages at the maternal-fetal interface. Hum Reprod 2005; 20: 1057-1066. (Pubitemid 40667856)
75. Winnall WR, Muir JA, Hedger MP,. Rat resident testicular macrophages have an alternatively activated phenotype and constitutively produce interleukin-10 in vitro. J Leukoc Biol 2011; 90: 133-143.
76. Laskarin G, Redzovic A, Rubesa Z, et al,. Decidual natural killer cell tuning by autologous dendritic cells. Am J Reprod Immunol 2008; 59: 433-445. (Pubitemid 351524233)
77. Bellora F, Castriconi R, Dondero A, et al,. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci USA 2010; 107: 21659-21664.
78. + myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci USA 2010; 107: 11918-11923.
79. Zaiss MM, Kurowska-Stolarska M, Bohm C, et al,. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNFα-mediated bone loss. J Immunol 2011; 186: 6097-6105.
80. O'Brien J, Lyons T, Monks J, et al,. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol 2010; 176: 1241-1255.
81. Liddiard K, Rosas M, Davies LC, et al,. Macrophage heterogeneity and acute inflammation. Eur J Immunol 2011; 41: 2503-2508.
82. Jenkins SJ, Ruckerl D, Cook PC, et al,. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011; 332: 1284-1288.
83. Bystrom J, Evans I, Newson J, et al,. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 2008; 112: 4117-4127.
84. Serhan CN, Chiang N, Van Dyke TE,. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-361. (Pubitemid 351595216)
85. Lawrence T, Willoughby DA, Gilroy DW,. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002; 2: 787-795. (Pubitemid 37328718)
86. Serhan CN, Yang R, Martinod K, et al,. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206: 15-23.
87. Schif-Zuck S, Gross N, Assi S, et al,. Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol 2011; 41: 366-379.
88. Mosca M, Polentarutti N, Mangano G, et al,. Regulation of the microsomal prostaglandin E synthase-1 in polarized mononuclear phagocytes and its constitutive expression in neutrophils. J Leukoc Biol 2007; 82: 320-326. (Pubitemid 47230643)
89. Lucas T, Waisman A, Ranjan R, et al,. Differential roles of macrophages in diverse phases of skin repair. J Immunol 2010; 184: 3964-3977.
90. Serhan CN, Fredman G, Yang R, et al,. Novel proresolving aspirin-triggered DHA pathway. Chem Biol 2011; 18: 976-987.
91. Mares CA, Sharma J, Li Q, et al,. Defect in efferocytosis leads to alternative activation of macrophages in Francisella infections. Immunol Cell Biol 2011; 89: 167-172.
92. Al-Mulla F, Leibovich SJ, Francis IM, et al,. Impaired TGFβ signaling and a defect in resolution of inflammation contribute to delayed wound healing in a female rat model of type 2 diabetes. Mol Biosyst 2011; 7: 3006-3020.
93. Sindrilaru A, Peters T, Wieschalka S, et al,. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 2011; 121: 985-997.
94. Kobayashi M, Jeschke MG, Shigematsu K, et al,. M2b monocytes predominated in peripheral blood of severely burned patients. JImmunol 2010; 185: 7174-7179.
95. Swirski FK, Nahrendorf M, Etzrodt M, et al,. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325: 612-616.
96. Swaminathan S, Griffin MD,. First responders: understanding monocyte-lineage traffic in the acutely injured kidney. Kidney Int 2008; 74: 1509-1511.
97. Lambert JM, Lopez EF, Lindsey ML,. Macrophage roles following myocardial infarction. Int J Cardiol 2008; 130: 147-158.
98. Troidl C, Mollmann H, Nef H, et al,. Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med 2009; 13: 3485-3496.
99. Ricardo SD, van Goor H, Eddy AA,. Macrophage diversity in renal injury and repair. J Clin Invest 2008; 118: 3522-3530.
100. Takeda Y, Costa S, Delamarre E, et al,. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 2011; 479: 122-126.
101. Ransohoff RM, Cardona AE,. The myeloid cells of the central nervous system parenchyma. Nature 2010; 468: 253-262.
102. Murray PJ, Wynn TA,. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 2011; 89: 557-563.
103. Babu S, Blauvelt CP, Kumaraswami V, et al,. Chemokine receptors of T cells and of B cells in lymphatic filarial infection: a role for CCR9 in pathogenesis. J Infect Dis 2005; 191: 1018-1026. (Pubitemid 40349822)
104. Brys L, Beschin A, Raes G, et al,. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol 2005; 174: 6095-6104. (Pubitemid 40663798)
105. Pearce EJ, MacDonald AS,. The immunobiology of schistosomiasis. Nat Rev Immunol 2002; 2: 499-511. (Pubitemid 37328741)
106. Porta C, Rimoldi M, Raes G, et al,. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor-κB. Proc Natl Acad Sci USA 2009; 106: 14978-14983.
107. Herbert DR, Holscher C, Mohrs M, et al,. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 2004; 20: 623-635. (Pubitemid 38659504)
108. Kim HY, DeKruyff RH, Umetsu DT,. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol 2010; 11: 577-584.
109. Melgert BN, ten Hacken NH, Rutgers B, et al,. More alternative activation of macrophages in lungs of asthmatic patients. J Allergy Clin Immunol 2011; 127: 831-833.
110. Wynn TA,. IL-13 effector functions. Annu Rev Immunol 2003; 21: 425-456. (Pubitemid 37174537)
111. Moreira AP, Hogaboam CM,. Macrophages in allergic asthma: fine-tuning their pro- and anti-inflammatory actions for disease resolution. J Interferon Cytokine Res 2011; 31: 485-491.
112. Murray LA, Chen Q, Kramer MS, et al,. TGFβ driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol 2011; 43: 154-162.
113. Murray LA, Rosada R, Moreira AP, et al,. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PloS One 2010; 5: e9683.
114. Zhang W, Xu W, Xiong S,. Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol 2011; 187: 1764-1777.
115. Castano AP, Lin SL, Surowy T, et al,. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Translat Med 2009; 1: 5ra13.
116. Vidal B, Serrano AL, Tjwa M, et al,. Fibrinogen drives dystrophic muscle fibrosis via a TGFβ/alternative macrophage activation pathway. Genes Dev 2008; 22: 1747-1752. (Pubitemid 351915499)
117. Bottazzi B, Doni A, Garlanda C, et al,. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010; 28: 157-183.
118. Dvorak HF,. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659. (Pubitemid 17052899)
119. Mantovani A, Allavena P, Sica A, et al,. Cancer-related inflammation. Nature 2008; 454: 436-444.
120. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545. (Pubitemid 32173595)
121. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
122. Mantovani A, Bottazzi B, Colotta F, et al,. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13: 265-270.
123. Hagemann T, Biswas SK, Lawrence T, et al,. Regulation of macrophage function in tumors: the multifaceted role of NF-κB. Blood 2009; 113: 3139-3146.
124. Hagemann T, Wilson J, Burke F, et al,. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. JImmunol 2006; 176: 5023-5032.
125. Movahedi K, Laoui D, Gysemans C, et al,. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70: 5728-5739.
126. Allavena P, Sica A, Vecchi A, et al,. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev 2000; 177: 141-149.
127. Ruffell B, Affara NI, Coussens LM,. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012; 33: 119-126.
128. + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
129. Doedens AL, Stockmann C, Rubinstein MP, et al,. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Cancer Res 2010; 70: 7465-7475.
130. Qian BZ, Pollard JW,. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
131. Andreu P, Johansson M, Affara NI, et al,. FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010; 17: 121-134.
132. Loges S, Schmidt T, Tjwa M, et al,. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood 2010; 115: 2264-2273.
133. Lin EY, Li JF, Gnatovskiy L, et al,. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006; 66: 11238-11246. (Pubitemid 46009952)
134. + macrophages within the immediate sprouting microenvironment. Blood 2010; 115: 5053-5056.
135. Nagakawa Y, Aoki T, Kasuya K, et al,. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 2002; 24: 169-178. (Pubitemid 34171293)
136. Huang S, Van Arsdall M, Tedjarati S, et al,. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002; 94: 1134-1142. (Pubitemid 34919050)
137. Solinas G, Schiarea S, Liguori M, et al,. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol 2010; 185: 642-652.
138. Murdoch C, Muthana M, Coffelt SB, et al,. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8: 618-631.
139. Schmidt T, Carmeliet P,. Blood-vessel formation: bridges that guide and unite. Nature 2010; 465: 697-699.
140. Hotchkiss KA, Ashton AW, Klein RS, et al,. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003; 63: 527-533. (Pubitemid 36152517)
141. Schoppmann SF, Birner P, Stockl J, et al,. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161: 947-956. (Pubitemid 34988382)
142. Fantin A, Vieira JM, Gestri G, et al,. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 2010; 116: 829-840.
143. Murdoch C, Giannoudis A, Lewis CE,. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104: 2224-2234. (Pubitemid 39331817)
144. Marchesi F, Locatelli M, Solinas G, et al,. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol 2010; 224: 39-44.